LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in an oversubscribed Series B financing. Syncona has committed £19.9 million as part of a leading Series B syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient…
Tag: Series B Financing
Climate tech company, GALY, raises $33 million in Series B financing
LONDON: Agronomics’ portfolio company GALY CO. has closed an oversubscribed US$ 33 million Series B financing led by Breakthrough Energy Ventures LLC, with additional participation from new investors H&M Group Ventures and Industria de Diseño Textil, S.A. (through Mundi Ventures). Founded in 2019 with a mission to find ethical and sustainable agricultural solutions, GALY Cotton is…
Beacon Therapeutics raises $170 million in a Series B financing
Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon Therapeutics, a leading ophthalmic gene therapy company
Syncona co-leads Series B financing in Quell Therapeutics of up to $156 million
LONDON, UK: Syncona Ltd has committed $25 million (£19 million) to Quell Therapeutics, a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, in an up to $156 million (£117 million) Series B financing. Syncona co-led the financing round alongside specialist global institutional investors Jeito Capital,…
CinCor Pharma raises $143 million in Series B Financing
LONDON, UK: RTW Venture Fund Limited notes the announcement by CinCor Pharma Inc. on 12 October 2021 of its completion of a US$143 million Series B financing round. The Company, alongside other investment vehicles of RTW Investments, LP, confirms that it participated in the Series B financing round together with other investors. CinCor is a…